Equity grants to Carlisle (NYSE: CSL) VP & CHRO Susan Wallace

Rhea-AI Filing Summary

Carlisle Companies executive Susan Wallace, VP & CHRO, reported new equity awards. On January 28, 2026, she received a grant of 675 shares of restricted common stock, bringing her directly held common shares to 2,026.

She was also granted an employee stock option for 2,355 shares of common stock with an exercise price of $341.01 per share. The option vests in three equal annual installments beginning on January 28, 2027, aligning her compensation more closely with long-term shareholder value.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wallace Susan

(Last) (First) (Middle)

16430 N SCOTTSDALE RD

STE 400

(Street)

SCOTTSDALE AZ 85254

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CARLISLE COMPANIES INC [ CSL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP & CHRO

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		675(1)	A	$0	2,026	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$341.01	01/28/2026		A		2,355		(2)	01/27/2036	Common Stock	2,355	$0	2,355	D

Explanation of Responses:

1. Represents a grant of 675 restricted shares from the issuer as an executive officer of the issuer.

2. The option vests in three equal annual installments beginning on January 28, 2027.

Remarks:

	/s/ Susan Wallace by Ronald P. Fuss, attorney-in-fact	01/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Carlisle (CSL) report for Susan Wallace?

Susan Wallace reported two equity grants from Carlisle. She received 675 restricted common shares and an employee stock option for 2,355 shares, both dated January 28, 2026, as part of her compensation as VP & CHRO.

How many Carlisle (CSL) common shares does Susan Wallace now own directly?

After the reported grant, Susan Wallace directly owns 2,026 common shares. This figure includes the newly granted 675 restricted shares and reflects her total beneficial ownership of Carlisle common stock reported in this Form 4.

What are the terms of Susan Wallace’s new stock options at Carlisle (CSL)?

Wallace received options for 2,355 Carlisle shares at a $341.01 exercise price. These employee stock options vest in three equal annual installments beginning January 28, 2027, encouraging longer-term alignment with company performance.

Are Susan Wallace’s new Carlisle (CSL) equity awards part of compensation?

Yes, both awards are compensation-related grants. The filing states the 675 restricted shares were granted to her as an executive officer, and the 2,355-share employee stock option is a standard incentive structure tied to future vesting.

When do Susan Wallace’s Carlisle (CSL) stock options start vesting?

The options begin vesting on January 28, 2027. They vest in three equal annual installments, meaning portions of the 2,355-share grant become exercisable over three years starting on that date.